AMDL, Inc. (“AMDL”) is listed on the American Stock Exchange under the symbol (“ADL”). The Company is a vertically integrated specialty pharmaceutical company. In combination with its subsidiary Jade Pharmaceutical, Inc. (“JPI”) the Company engages in the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in the People's Republic of China (“China”). AMDL currently employs approximately 320 people of which 311 are in China.
AMDL was founded in 1987 as a small bio-tech research and development firm that had one product, its proprietary cancer diagnostic test: DR-70®. In 2001, AMDL acquired a proprietary cancer vaccine Combination Immunogene therapy (“CIT”). CIT is a US patented technology (patent issued May 25, 2004). In September 2006, AMDL acquired JPI in order to dramatically broaden AMDL’s business into a multi segmented China-centric pharmaceutical business.
Keywords: pharmaceutical nutritional supplement cosmetic products
cancer DR-70